You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 26, 2024

Patent: 10,624,814


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,624,814
Title:Container for a solution of human plasma proteins and method for obtaining thereof
Abstract: A container for a solution of human plasma proteins has a primary inner bag made up of a first multilayer polymer film with two outer layers of polyethylene (PE) and an intermediate layer of ethylene vinyl alcohol (EVOH) copolymer, and a secondary outer bag made up of a second multilayer film with layers of polyethylene terephthalate (PET)-silicon oxides (SiOx), oriented polyamide (OPA), polypropylene (PP)-silicon oxides (SiOx) and polypropylene (PP), referred to as multilayer PP-SiOx.
Inventor(s): Roura Fernandez; Carlos (San Juan Despi, ES), Garcia Garcia; Jose Antonio (Las Torres Cotillas, ES), Llorens Masas; Estela (Parets del Valles, ES), Marzo Adam; Nuria (Parets del Valles, ES)
Assignee: GRIFOLS, S.A. (Barcelona, ES)
Application Number:15/611,582
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Analyzing the Claims and Patent Landscape of United States Patent 10,624,814

Introduction

The United States patent system is a complex and evolving field, particularly with the advent of new technologies and legislative changes. This analysis will delve into the specifics of United States Patent 10,624,814, examining its claims, the broader patent landscape, and the relevant legal and procedural frameworks.

Background: The Leahy-Smith America Invents Act (AIA)

The 2011 Leahy-Smith America Invents Act (AIA) is a pivotal piece of legislation that significantly altered the U.S. patent landscape. It introduced the Patent Trial and Appeal Board (PTAB) and new administrative challenges such as inter partes review (IPR) and post-grant review (PGR), which have become crucial tools for challenging patent validity[1].

Patent Trial and Appeal Board (PTAB)

PTAB, established by the AIA, is a tribunal within the U.S. Patent and Trademark Office (USPTO) that hears challenges to the validity of patents. These challenges are typically decided by a panel of three administrative patent judges (APJs). PTAB processes are generally faster and less expensive than judicial proceedings, with a lower burden of proof to invalidate patents[1].

Patent Validity and Challenges

Patents carry a presumption of validity when challenged in court, requiring clear and convincing evidence to demonstrate invalidity. In contrast, PTAB proceedings require only a preponderance of the evidence to invalidate patent claims. This difference makes PTAB a more attractive option for entities accused of patent infringement[1].

Claims Analysis: Novelty and Nonobviousness

For a patent to be granted, the claimed invention must meet the novelty and nonobviousness requirements. The invention must be new and not previously disclosed in the prior art. Additionally, it must be nonobvious, meaning it must not be an obvious combination of existing knowledge to a person of ordinary skill in the relevant field[1].

Subject Matter Eligibility

The USPTO has issued guidance on patent subject matter eligibility, particularly for AI inventions. Claims must fall into one of the four statutory categories (processes, machines, manufactures, and compositions of matter) and must not be directed to judicial exceptions such as abstract ideas, laws of nature, or natural phenomena. For AI inventions, the claims must integrate the judicial exception into a practical application, improving the functioning of a computer or another technology[4].

AI-Assisted Inventions and Patent Applications

The use of AI tools in drafting and editing patent applications is becoming more common. However, practitioners must ensure that all statements in the paper are true and based on information believed to be true. If an AI tool makes material contributions to the invention, this must be disclosed to the USPTO. The contributions made by natural persons must rise to the level of inventorship, and the specification must clearly describe how the claimed invention improves existing technological processes[3][4].

Specific Analysis of United States Patent 10,624,814

To conduct a comprehensive analysis of this patent, several key aspects must be considered:

Claims Review

  • Each claim must be scrutinized for novelty, nonobviousness, and subject matter eligibility.
  • The claims should be evaluated to determine if they integrate any judicial exceptions into a practical application, especially if the patent involves AI or other advanced technologies[4].

Prior Art Analysis

  • A thorough search of prior art is necessary to ensure that the claimed invention is new and not obvious.
  • This involves reviewing existing patents, publications, and public disclosures to verify that the invention adds something new to the total stock of knowledge[1].

PTAB and Judicial Challenges

  • If the patent is challenged, whether through IPR, PGR, or judicial proceedings, the strength of the claims and the evidence supporting them will be crucial.
  • The lower burden of proof in PTAB proceedings makes it a critical venue for challenging patent validity[1].

AI Tool Contributions

  • If AI tools were used in drafting or editing the patent application, it is essential to disclose this and ensure that the contributions made by natural persons meet the criteria for inventorship[3].

Case Law and Precedents

Recent case law, such as the decisions in In re Cellect, highlights the importance of obviousness-type double patenting (ODP) analysis and the proper handling of terminal disclaimers. These precedents can influence how patent claims are evaluated and challenged[5].

Practical Applications and Technological Improvements

For patents involving AI or other advanced technologies, the specification must clearly describe how the claimed invention improves existing technological processes. This documentation is critical in demonstrating that the claim is not merely an abstract idea but a practical application that enhances technology[4].

Ethical and Legal Considerations

The use of AI in patent applications raises ethical and legal questions. Practitioners must ensure that AI-generated content is accurate and does not introduce false or misleading information. The USPTO's guidance emphasizes the need for careful review and verification of all documents prepared with AI assistance[3].

Future Trends and Implications

The increasing use of AI in patent applications and the evolving landscape of patent law suggest that future patents will need to be carefully crafted to meet the stringent criteria for subject matter eligibility and to integrate judicial exceptions into practical applications. The role of PTAB and other administrative challenges will continue to be significant in shaping the patent landscape[4].

Key Takeaways

  • Novelty and Nonobviousness: Ensure that the claimed invention is new and not obvious.
  • Subject Matter Eligibility: Claims must integrate judicial exceptions into practical applications.
  • AI Contributions: Disclose AI tool contributions and ensure they meet inventorship criteria.
  • PTAB Challenges: Be prepared for faster and less expensive administrative challenges.
  • Ethical and Legal Compliance: Verify the accuracy of AI-generated content.

Frequently Asked Questions

Q: What is the significance of the Leahy-Smith America Invents Act (AIA) in the U.S. patent landscape? A: The AIA introduced the Patent Trial and Appeal Board (PTAB) and new administrative challenges like IPR and PGR, which have significantly impacted how patent validity is challenged.

Q: How does the use of AI tools affect patent applications? A: AI tools can assist in drafting and editing, but practitioners must ensure all statements are true and based on believed information. Material contributions by AI must be disclosed.

Q: What are the key requirements for patent subject matter eligibility? A: Claims must fall into one of the four statutory categories and not be directed to judicial exceptions. For AI inventions, claims must integrate the judicial exception into a practical application.

Q: Why is prior art analysis important in patent claims review? A: Prior art analysis ensures that the claimed invention is new and not obvious, verifying that it adds something new to the total stock of knowledge.

Q: How do PTAB proceedings differ from judicial proceedings in challenging patent validity? A: PTAB proceedings are generally faster and less expensive, requiring only a preponderance of the evidence to invalidate patent claims, unlike the clear and convincing evidence required in judicial proceedings.

Cited Sources

  1. Congressional Research Service, "The Patent Trial and Appeal Board and Inter Partes Review," Updated May 28, 2024.
  2. Google Patents, "US20110138338A1 - Patent Claims Analysis System and Method."
  3. Buchanan Ingersoll & Rooney PC, "U.S. Patent Office Issues Additional Guidance on Use of AI Tools," April 15, 2024.
  4. Greenberg Traurig LLP, "USPTO Issues New Guidance on Patent Subject Matter Eligibility for AI Inventions," July 19, 2024.
  5. United States Court of Appeals for the Federal Circuit, "In re Cellect," August 28, 2023.

More… ↓

⤷  Subscribe

Details for Patent 10,624,814

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Octapharma Pharmazeutika Produktionsges.m.b.h. OCTAPLAS pooled plasma (human), solvent/detergent treated For Injection 125416 January 17, 2013 ⤷  Subscribe 2036-09-16
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.